Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate in the following investor conferences in September and October:
| SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate in the following investor conferences in September and October:
UBS Private Company Conference Cantor Fitzgerald Healthcare Conference Needham Biotech Private Company 1x1 Forum Archived versions of the virtual presentations/fire-side chats will be available through the Aristea website at www.aristeatx.com following the conferences. About Aristea Therapeutics Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2b clinical development. Aristea is headquartered in San Diego, CA. To learn more, please visit www.aristeatx.com and follow us on social media @Aristeatx For media inquiries contact:
SOURCE Aristea Therapeutics |
View original content to download multimedia:
